$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$ Reviva Pharmaceuticals Holdings (RVPH) Roth MKM analyst reiterated a Buy rating on Reviva Pharmaceuticals Holdings today and set a price target of $3.00. The company’s shares closed last Friday at $0.55. According to , Pachaiyappan has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.2% and a 37.8% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Entrada Therapeutics Inc, Capricor Therapeutics, and Avidity Biosciences. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Reviva Pharmaceuticals Holdings with a $3.20 average price target, a 499.3% upside from current levels. In a report issued on September
$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$ activity swept through select biotech and medical device names Thursday, with several micro- and mid-cap stocks posting sharp gains following session-end catalysts, volume spikes, or pipeline updates. Below are key price moves and developments from RVPH, PEN, PALI, IOBT, RLYB, and VOR. Reviva Pharmaceuticals Holdings Inc. (RVPH) extended its explosive rally into after-hours trading Thursday, jumping 18.27% to $0.58 following a 35.1% surge during the regular session. The move came on a staggering volume of over 40.5 million shares, nearly nine times its daily average. RVPH traded between $0.3700 and $0.5338 intraday, and the stock remains well below its 52-week high of $4.28. Reviva Pharm Holding